These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38103161)

  • 41. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
    Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM
    Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.
    Martin-Orozco N; Vale N; Mihic A; Amor T; Reiter L; Arita Y; Samson R; Hu Q; Gingras AC; Sorenson BT; Marcusson EG; Patel P
    Sci Rep; 2023 May; 13(1):8557. PubMed ID: 37236995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
    Gunale B; Kapse D; Kar S; Bavdekar A; Kohli S; Lalwani S; Meshram S; Raut A; Kulkarni P; Samuel C; Munshi R; Gupta M; Plested JS; Cloney-Clark S; Zhu M; Pryor M; Hamilton S; Thakar M; Shete A; Dharmadhikari A; Bhamare C; Shaligram U; Poonawalla CS; Mallory RM; Glenn GM; Kulkarni PS;
    JAMA Pediatr; 2023 Jul; 177(9):911-20. PubMed ID: 37523166
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine.
    Huang J; Qiu Y; Luo L; Wu J; Hu D; Zhong X; Lin J; Guo L; Yang H; Li C; Wang X
    J Med Virol; 2024 Mar; 96(3):e29542. PubMed ID: 38506170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
    PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
    Masuda T; Murakami K; Sugiura K; Sakui S; Philip Schuring R; Mori M
    Vaccine; 2022 Mar; 40(13):2044-2052. PubMed ID: 35177302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
    Bravo L; Smolenov I; Han HH; Li P; Hosain R; Rockhold F; Clemens SAC; Roa C; Borja-Tabora C; Quinsaat A; Lopez P; López-Medina E; Brochado L; Hernández EA; Reynales H; Medina T; Velasquez H; Toloza LB; Rodriguez EJ; de Salazar DIM; Rodríguez CA; Sprinz E; Cerbino-Neto J; Luz KG; Schwarzbold AV; Paiva MS; Carlos J; Montellano MEB; de Los Reyes MRA; Yu CY; Alberto ER; Panaligan MM; Salvani-Bautista M; Buntinx E; Hites M; Martinot JB; Bhorat QE; Badat A; Baccarini C; Hu B; Jurgens J; Engelbrecht J; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R
    Lancet; 2022 Jan; 399(10323):461-472. PubMed ID: 35065705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial.
    Kudriavtsev AV; Vakhrusheva AV; Kryuchkov NA; Frolova ME; Blagodatskikh KA; Ivanishin TV; Djonovic M; Romanovskaya-Romanko EA; Kovalenko AN; Lioznov DA; Zubkova TG; Teplykh SV; Oseshnyuk RA; Stukova MA; Isaev AA; Krasilnikov IV
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851204
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Masuda T; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
    Vaccine; 2022 May; 40(24):3380-3388. PubMed ID: 35501178
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations.
    Tabarsi P; Anjidani N; Shahpari R; Mardani M; Sabzvari A; Yazdani B; Roshanzamir K; Bayatani B; Taheri A; Petrovsky N; Li L; Barati S
    Clin Microbiol Infect; 2022 Sep; 28(9):1263-1271. PubMed ID: 35436611
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.
    Kaabi NA; Yang YK; Liang Y; Xu K; Zhang XF; Kang Y; Jin YQ; Hou JW; Zhang J; Yang T; Hussein S; ElDein MS; Lei ZH; Zhang H; Shao S; Liu ZM; Liu N; Zheng X; Su JG; Yang SS; Cong X; Tan Y; Lei W; Gao XJ; Jiang Z; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Xiao P; Shen FJ; Wu JJ; Han ZB; Du LF; Tang F; Chen S; Ma ZJ; Zheng F; Hou YN; Li XY; Li X; Wang ZN; Yin JL; Mao XY; Zhang J; Qu L; Zhang YT; Yang XM; Wu G; Li QM
    Signal Transduct Target Ther; 2023 Jan; 8(1):20. PubMed ID: 36596779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N;
    Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial.
    Hu J; Liu Y; Liu S; Shu Q; Yang X; Chu K; Qiao Y; Hu Y; Wang K; Pan H
    Front Immunol; 2023; 14():1241153. PubMed ID: 37799724
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.
    Pan HX; Liu JK; Huang BY; Li GF; Chang XY; Liu YF; Wang WL; Chu K; Hu JL; Li JX; Zhu DD; Wu JL; Xu XY; Zhang L; Wang M; Tan WJ; Huang WJ; Zhu FC
    Chin Med J (Engl); 2021 Apr; 134(11):1289-1298. PubMed ID: 33928916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
    Chu L; McPhee R; Huang W; Bennett H; Pajon R; Nestorova B; Leav B;
    Vaccine; 2021 May; 39(20):2791-2799. PubMed ID: 33707061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.